

Ranking

[All criteria](#)
[Management](#)
[Public Policy](#)
[R&D](#)
[Pricing](#)
[Patents](#)
[Capability](#)
[Donations](#)

1	GlaxoSmithKline plc	3.8
2	Johnson & Johnson	3.6
3	Sanofi	3.2
4	Merck & Co. Inc.	3.1
5	Gilead Sciences	3.0
6	Novo Nordisk A/S	3.0
7	Novartis AG	2.9
8	Merck KGaA	2.5
9	Bayer AG	2.4
10	Roche Holding Ltd.	2.3
11	Pfizer Inc.	2.2
12	Bristol-Myers Squibb Co.	2.1

Overall Ranking Index 2012

The 2012 Access to Medicine Index was published on November 28th, 2012. The report evaluates the top 20 pharmaceutical companies' access to medicine activities.

Click on a company name to find out more about its 2012 Index performance, or use the tabs at the top to see company rankings in specific areas.

Scores

Company scores are calculated on a relative scale of 0 to 5, with 0 indicating the lowest score among the company set and 5 signifying the highest score among the company set. Scores in this graph have been rounded to the nearest tenth for easier reading, but unrounded scores were used in all

13	Abbott Laboratories Inc.	2.0
14	Eli Lilly & Company	2.0
15	Eisai Co. Ltd.	1.9
16	AstraZeneca plc	1.6
17	Boehringer-Ingelheim	1.5
18	Takeda Pharmaceutical Co.	1.1
19	Daiichi Sankyo Co. Ltd.	0.9
20	Astellas Pharma Inc.	0.9

calculations.

Resources

For additional clarification and background information, please consult the Resources page.

247

Publications

- › 2010 Access to Medicine Index
- › 2012 Methodology Report - Stakeholder Review
- › Full Report 2012 Access to Medicine Index

Stay up to date

- › Twitter Access to Medicine Index
- › Twitter Wim Leereveld
- › LinkedIn Access to Medicine Foundation
- › Newsletter
- › RSS

Contact

Scheepmakersdijk 5A
2011 AS Haarlem
The Netherlands
+31 23 533 91 87
› info@atmindex.org

© 2012 Access to Medicine Foundation. All Rights Reserved. | [Disclaimer](#)